Price range: £35.00 through £150.00
Tirzepatide 30mg Dual GIP/GLP-1 receptor agonist. SURMOUNT-1 trial: mean 22.5% body weight change at 72 weeks (15mg).
Tirzepatide is a dual GIP/GLP-1 receptor agonist studied for its effects on metabolic parameters and body composition. The SURMOUNT–1 trial demonstrated significant outcomes over 72 weeks. Administer subcutaneously once weekly on a consistent day.
Tirzepatide 30mg Dual GIP/GLP-1 receptor agonist. SURMOUNT-1 trial: mean 22.5% body weight change at 72 weeks (15mg).
Tirzepatide is a dual GIP/GLP-1 receptor agonist studied for its effects on metabolic parameters and body composition. The SURMOUNT–1 trial demonstrated significant outcomes over 72 weeks. Administer subcutaneously once weekly on a consistent day.
| Quantity Og Vials | 1 Vial, 3 Vials, 5 Vials |
|---|
Be the first to review “Tirzepatide 30mg”
Related products
peptides
peptides
peptides
peptides
peptides
peptides
peptides
Reviews
There are no reviews yet.